CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the role of lipid droplets in Acute Myeloid Leukemia, focusing on their impact on cancer cell behavior and treatment resistance. By utilizing advanced laboratory techniques, the research aims to uncover new therapeutic strategies targeting lipid metabolism to improve treatment outcomes for AML…
Acute Myeloid Leukemia (AML) results from the uncontrolled expansion of differentiation-defective hematopoietic stem/progenitor cells or immature myeloid cells (blasts) in the bone marrow (BM). AML remains a high-risk disease mainly due to treatment refractoriness which is dependent on leukemia-BM stroma interactions.
Unfortunately, treatments have only experienced minor developments over the last decades.
On the other hand, emerging evidence in cancer metabolism has identified Lipid Droplets (L…
INSTITUT JOSEP CARRERAS - CERCA
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
ONECHAIN IMMUNOTHERAPEUTICS S.L.
Spain, BARCELONA
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
